Insider Selling: Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells $1,364,372.56 in Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Pushkal Garg sold 3,022 shares of the firm’s stock in a transaction that occurred on Friday, October 3rd. The stock was sold at an average price of $451.48, for a total transaction of $1,364,372.56. Following the sale, the executive vice president directly owned 20,221 shares in the company, valued at $9,129,377.08. The trade was a 13.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Pushkal Garg also recently made the following trade(s):

• On Thursday, October 2nd, Pushkal Garg sold 2,937 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $452.05, for a total transaction of $1,327,670.85.
• On Tuesday, August 19th, Pushkal Garg sold 1,455 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $458.41, for a total transaction of $666,986.55.
• On Monday, August 18th, Pushkal Garg sold 1,396 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $453.27, for a total transaction of $632,764.92.

Alnylam Pharmaceuticals Trading Down 1.0%

ALNY stock opened at $456.35 on Monday. Alnylam Pharmaceuticals, Inc. has a 52-week low of $205.87 and a 52-week high of $484.21. The company has a quick ratio of 2.75, a current ratio of 2.80 and a debt-to-equity ratio of 4.10. The firm has a market cap of $59.82 billion, a P/E ratio of -184.76 and a beta of 0.36. The company’s 50-day simple moving average is $441.57 and its 200-day simple moving average is $339.95.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.86. The firm had revenue of $773.69 million during the quarter, compared to analyst estimates of $633.54 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.Alnylam Pharmaceuticals’s revenue for the quarter was up 17.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.13) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. SVB Wealth LLC purchased a new stake in Alnylam Pharmaceuticals in the first quarter valued at $27,000. Whipplewood Advisors LLC raised its holdings in Alnylam Pharmaceuticals by 208.8% in the 1st quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 71 shares during the period. Bessemer Group Inc. raised its holdings in Alnylam Pharmaceuticals by 176.9% in the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 69 shares during the period. Atlantic Union Bankshares Corp acquired a new position in Alnylam Pharmaceuticals in the second quarter valued at about $30,000. Finally, Elevation Point Wealth Partners LLC purchased a new position in Alnylam Pharmaceuticals during the second quarter worth about $37,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on ALNY. Morgan Stanley increased their target price on Alnylam Pharmaceuticals from $312.00 to $405.00 and gave the company an “equal weight” rating in a research report on Friday, August 1st. BMO Capital Markets increased their price objective on shares of Alnylam Pharmaceuticals from $450.00 to $470.00 and gave the company an “outperform” rating in a report on Friday, September 5th. Piper Sandler boosted their target price on shares of Alnylam Pharmaceuticals from $304.00 to $449.00 and gave the stock an “overweight” rating in a research note on Friday, August 1st. Weiss Ratings restated a “sell (d-)” rating on shares of Alnylam Pharmaceuticals in a research report on Saturday, September 27th. Finally, Royal Bank Of Canada lifted their price objective on Alnylam Pharmaceuticals from $435.00 to $500.00 and gave the stock an “outperform” rating in a report on Friday, September 19th. Twenty-four equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $439.58.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.